Boustead Singapore's (SGX:F9D) real estate solutions division business secured a major design-and-build contract for an integrated pharmaceutical manufacturing and R&D facility situated within Tuas Biomedical Park, Singapore, according to a Friday filing with the Singapore Exchange.
The project is expected to complete by the third quarter of 2026 and takes the real estate solutions division's order backlog to SG$249 million and the group's engineering order backlog to SG$428 million, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.